Autographa califomica multicapsid nuclear polyhedrosis virus-infected insect cells express a viral immediateearly transcriptional regulatory protein, IEl, that has been shown by transient-expression assays to stimulate the expression of certain baculovirus delayed-early (DE) DE (16, 17) and L (19) gene promoters, an activity termed enhancer independent. Two independent studies have also demonstrated that the IE1 gene product of both AcMNPV (29) 
of IE1, is required for inhibitory and DNA-binding activities. Several nontransactivating TEl mutants trans-dominantly interfered with wild-type IEl transactivation of enhancer-linked DE genes. trans-dominant interference was expressed only by IE1 mutants that retained the N-terminal putative acidic activation domain, suggesting that this region may be involved in associations with a factor(s) essential for activation of enhancer-linked genes.
Viruses have served as model systems for studies of gene expression and regulation in both prokaryotic and eukaryotic cellular systems. Viral gene expression is tightly regulated by interactions between viral and host cell factors. Most viruses express their genes in temporally ordered tiers that can be classified according to their kinetics of expression, dependence on viral DNA replication, and requirement for the prior expression of one or more viral regulatory factors. Baculovirus genes have been grouped into three temporal classes: early (E), late (L), and very late (VL; for a review, see reference 1). E genes are distinguished from L and VL genes in that their expression is independent of viral DNA replication. Additionally, E genes are transcribed by an a-amanitin-sensitive RNA polymerase II activity, whereas L and VL transcription is controlled by a virus-encoded/regulated cx-amanitin-insensitive activity (22) . E genes have been further divided into two subgroups (immediate-early [IE] genes and delayed-early [DE] genes) on the basis of transient-expression (3, 16, 29) and cycloheximide blockage (25, 35) experiments. IE promoters are fully active in the absence of other viral factors. DE promoters require one or more IE gene products foj*full activation (3, 10, 16, 25, 35, 36 ), although some low-level expression may be detected in the absence of viral transactivators (41) . From several studies, it is believed that IE gene products function as viral gene regulators (3-5, 16, 18, 29, 30, 41) and that some DE factors control viral DNA replication (32, 37, 42) . L and VL genes encode structural proteins involved in viral encapsidation and polyhedron assembly. In sum, the entire baculovirus life cycle is believed to be initiated, in part, by IE gene products; a * Corresponding author. knowledge of the how these gene products function is central to the understanding of the biology of baculoviruses and the processes involved in the regulation of insect genes.
The IE1 gene of Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV) has been shown, on the basis of transient-expression experiments, to encode a multifunctional regulatory protein (4, 17, 29) . IE1 is transcribed from a single promoter throughout infection as an unspliced 1.9-kb RNA with an open reading frame (ORF) encoding a 70-kDa protein. A slightly longer form of IE1 (spliced-IEl or IEO [6] ) is transcribed early and late from two different start sites located approximately 4 kbp upstream of the IE1 promoter (28) . Studies have shown that IE1 induces the expression of several chimeric genes linked to DE (16, 17) and L (19) gene promoters, an activity termed enhancer independent. Two independent studies have also demonstrated that the IE1 gene product of both AcMNPV (29) and Orgia pseudotsugata multicapsid nuclear polyhedrosis virus (OpMNPV [41] ) has autoregulatory properties; i.e., it stimulates its own expression. IE1 not only transactivates promoters but also increases the transcription rate of several baculovirus and heterologous promoters cis-linked to homologous region (hr) enhancers, an activity termed enhancer dependent (17) . Insect cells transfected with IE1 contain an enhancer-specific DNA-binding activity (14) , leading us to believe that enhancer-dependent transactivation may be mediated by a direct interaction between the IE1 gene product and the viral enhancers. Lastly, IE1 not only stimulates gene expression but also inhibits the expression of chimeric genes linked to the IEO (29) and IEN (4) (40) .
Plasmid constructions. A schematic representation of all IE1 plasmids used in this study is shown in Fig. 1A . All recombinant plasmids were constructed in vitro by standard cloning techniques (34) and sequenced (39) . The wild-type IEl plasmid (pNheIEl) was derived from pIE1 (16) by digestion with NheI and SmaI, repair of the 5' extensions with the large fragment of DNA polymerase I, and subsequent religation. IEl C-terminal deletion mutants were constructed by inserting a synthetic deoxyoligonucleotide linker (pCTAGCTAGCTAG), encoding nonsense codons in all three reading frames, into convenient restriction sites within the IEl ORF. N-terminal mutants were derived from an IEl-encoding plasmid (29) The IE0/IE1 reporter (pGCAT) used in this study has been described previously (29) . Briefly, it contains the chloramphenicol acetyltransferase (CAT) gene cloned 36 bp downstream of the IE1 ATG in pH3G (HindITI G fragment of AcMNPV; 90.6 to 96.8 map units), and expresses IEOCAT and IElCAT fused gene products. The IE1 nonsense mutant (pIE1AORF [29] ), the DE 39-kDa reporters (39K reporters; p39CAT and p39CATQ- [17] ), and the plasmid IBI-24 (14) containing the hr5 enhancer have been previously described. The plasmid GC123 contains the IEO ORF (derived from its cDNA) cloned under the control of its native promoter; it was obtained from Dennis Henner and George Chisholm.
CAT assays. Transfections were done by the calcium phosphate precipitation method (16 (14) . A 252-bp fragment containing a portion of hr5 was derived from pIBI-24 and end labeled with T4 polynucleotide kinase essentially as described previously (14) . Protein-DNA complexes were separated by native gel electrophoresis and analyzed by autoradiography. (Fig. 1B) . Some C-terminal mutants have additional non-IEl-encoded amino acids at their C termini as a result of the synthetic linker used to introduce a translation termination signal. N-terminal mutants retain the native IE1 ATG translation initiation codon followed by sequences encoded by synthetic oligonucleotides inserted to maintain the proper reading frame.
A transient-expression assay was used to analyze the transactivation activities of IE1 deletion mutants. In these assays, wild-type or mutant IE1 and either p39CAT (enhancerless) or p39CATQ-(hr5 enhancer-plus) were cotransfected into Sf9 cells. One day later, cell extracts were prepared and assayed for CAT activity. The cumulative results of this assay show that both enhancer-independent ( Fig. 2A ) and enhancer-dependent ( Cells transfected with pA&2-16 consistently expressed 1.3-to 1.5-fold greater CAT activity than wild-type IEl-transfected cells did, whereas pA2-52-transfected cells expressed 0.5-to 0.75-fold less activity. The results of assays conducted with C-terminal mutants show that although deletion of 2 amino acids (A580-582) had no effect, deletions of 25 (A557-582), 68 (A514-582), or 267 (A315-582) residues ablated transactivation function.
To determine whether loss of transactivation was either caused by deletion of a functional domain(s) or by suboptimal expression and/or an inherent instability of the mutant gene products, we analyzed IE1 proteins in transfected Sf9 cells. For this experiment, a polyclonal rabbit antiserum raised against a bacterially expressed IE1 protein (7) was used in a radioimmunoprecipitation assay (Fig. 3 ). This antiserum specifically immunoprecipitated a protein of the expected molecular mass (70 kDa) of IE1 in transfected cells tion of A2-145, the various active and inactive IE1 mutants were expressed at approximately equivalent levels. In Fig. 2 we showed that A2-145 did not transactivate the 39K reporter plasmids to any measurable extent. Since we were not able to detect this polypeptide, we could not attribute its lack of transactivation activity to the deletion of a functional domain.
Analysis of the autoregulatory and inhibitory activities of 24 h posttransfection and analyzed for CAT activity (39CAT extracts were undiluted, whereas 39CATQ-extracts were diluted 1:1,000). The averages of three separate experiments are plotted as the level of transactivation relative to wild-type IEl.
TEl deletion mutants. As mentioned above, it has been shown that IEl stimulates expression from its own promoter (29, 41) , an activity we term autoregulation, and inhibits expression from the IEO promoter (41) . The experiment whose results are shown in Fig. 4 was done to determine whether the autoregulatory and inhibitory properties of IEl could be genetically separated. A reporter plasmid (GCAT; Fig. 4B ) that expresses fused CAT gene products under the control of both the IEO and IE1 promoters was transfected either alone or in the presence of wild-type or mutant TEl plasmids. We have previously shown that cotransfection of pGCAT with pNheTEl decreases IEOCAT expression approximately 5-fold and increases TElCAT expression 5-to 10-fold (29) (Fig. 4, compare lanes 2 and 4) . In addition, we showed that an IE1 nonsense mutant (IE1AORF) has no effect on IElCAT or IEOCAT expression (Fig. 4, compare  lanes 2 and 3) .
Cotransfection with mutant TEl plasmids showed that deletions of 15 or 51 residues from the N terminus did not affect either autoregulatory or inhibitory activities (Fig. 4 lanes 5 and 6, respectively). In Fig. 2 we noted that A2-145 did not transactivate the delayed-early 39K reporter plasmids. In this experiment, A2-145 also failed to transactivate IElCAT expression. However, it did inhibit IEOCAT expression to the same extent that wild-type IE1 did (Fig. 4,  compare lanes 4 and 7) , suggesting that the inhibitory and transactivation domains of IE1 may be separable. The fact that A2-145 inhibited IEO expression also suggests that the lack of transactivation (Fig. 2) by this mutant is probably a result of the loss of an activation domain and not the result of poor expression of the mutant gene product. Lastly, the absence of autoregulatory and inhibitory activities in mutants deleted for more than 25 C-terminal residues (Fig. 4 , lanes 9, 10, and 11) suggests that this region may be essential for these two activities.
Analysis of the DNA-binding properties of IEl deletion mutants. Recent evidence from our laboratories has suggested that IE1 may be an enhancer-binding protein (14) . The results of our functional assays with the deletion mutants prompted us to determine whether the loss of transactivation or inhibitory activities may result from the loss of a DNA-binding domain. An EMSA was conducted to determine which region(s) within IE1 is essential for DNAbinding activity. Sf9 cells were transfected with either wildtype or mutant IE1 plasmids, and 1 day later extracts were prepared and assayed by an EMSA with a double-stranded DNA probe derived from a plasmid which contains the hr5 enhancer element. Extracts prepared from cells transfected with pUC DNA (Fig. 5, lane 9 ) contained a nonspecific binding activity that was not affected by the addition of excess unlabeled probe (data not shown). Wild-type IEl and pA580-582-transfected cells contained an hr5-specific DNAbinding activity that resulted in the formation of at least two complexes (lanes 1 and 2, respectively) (Fig. 6) . The expression of p39CATQ-was decreased up to 10-fold by increasing the amount of pA557-582 (Fig. 6A) ; however, expression of p39CAT remained virtually unchanged (Fig. 6B) . These (29) in place of A557-582 showed that it had no effect on CAT expression from either reporter plasmid (data not shown), supporting the hypothesis that the inhibitory effect is mediated by the mutant IE1 gene product. These data do not rule out the possibility that the A557-582 gene product indirectly lowered 39CATQ-expression by inhibiting pNheIE1 expression. However, three lines of evidence argue against this hypothesis. First, as shown in Fig. 4 , A557-582 had no effect on IElCAT expression in pGCAT-transfected cells (compare lanes 2 and 9). Second, expression of an IElCAT reporter plasmid was not affected by pA557-582 in a cotransfection experiment (data not shown). Lastly, A557-582 had no effect on p39CAT expression (Fig. 6B) , suggesting that wild-type IE1 levels were unaffected. These results strongly suggest that the A557-582 gene product directly interferes with the enhancer-dependent transactivation function of IEl. We tested the remainder of the IEl deletion mutants in a similar assay in an attempt to isolate the region essential for interference activity. Since 5 ,ug of pA557-582 inhibited hr-linked CAT expression by approximately 90% (Fig. 6A) , we transfected Sf9 cells with p39CATQ-, 0.1 ,g of pNheIE1, and 5 ,ug of each IE1 mutant (Fig. 7) . The results of this experiment demonstrate that all three nontransactivating C-terminal mutants were able to interfere with IE1 enhancer-dependent transactivation. In contrast to the other nontransactivating mutants, A2-145 failed to demonstrate trans-dominant interference.
As expected, cells cotransfected with deletion mutants capable of transactivation expressed higher levels of CAT activity. Lastly, none of the nontransactivating mutants were able to interfere with the expression of p39CAT, suggesting that interference is enhancer dependent (data not shown).
A previous study in our laboratories demonstrated that IEO has enhancer-dependent transactivation activity (29) . Thus, we chose to investigate whether the trans-dominant mutant A557-582 also interferes with IEO-mediated transactivation. Sf9 cells were cotransfected with p39CATQ-, a constant amount of pGC123 (an IEO-expressing plasmid), and different amounts of pA557-582. CAT expression was assayed 1 day after transfection (Fig. 8) . Unexpectedly, A557-582 did not interfere with IEO-mediated transactivation; conversely, increasing the amount of pA557-582 augmented expression of p39CATQ-. CAT expression was stimulated approximately two-to fourfold by increasing amounts of pA557-582. In a control experiment in which various amounts of pA557-582 were cotransfected with an IEO reporter plasmid (IEOCAT), we found no significant effect on CAT expression (data not shown).
In summary, only mutant forms of IE1 that retained the N-terminal activation domain could trans-dominantly interfere with IEl-mediated transactivation. Furthermore, these mutants interfered only with the enhancer-dependent activation function of IE1; they had no effect on transactivation in DNA-binding region. If our working hypothesis is correct, the N-terminal activation domain should require a second region that confers specificity for target genes. The transientcotransfection assays we conducted showed consistently that deleting 25 or more amino acids from the C terminus resulted in loss of transactivation function. This could have been the result of either the loss of a second activation domain or, more consistent with our results, the deletion of a specificity domain. This domain may confer specificity to target genes directly (in the form of a DNA-binding domain) or indirectly (by serving as an interface for protein-protein interactions with factors bound to target genes). Although the EMSA used in this study does not distinguish between these two possibilities, it did allow us to investigate whether IE1 was a component of the protein-DNA complex.
Prior to this study, it had been demonstrated that cells transfected with IE1 DNA contained an hr5 enhancerspecific DNA-binding activity (14) . We believed that if the DNA-binding domain was contained within the C-terminal portion of the IE1 polypeptide, deletions from the N terminus that do not affect the binding domain should result in sequentially smaller IE1 gene products that form fastermigrating complexes in an EMSA. Our results demonstrate that IE1 forms a complex with hr5; however, we do not rule out the possibility of additional cellular proteins bound within these complexes.
Although sequence similarity was not found with any other DNA-binding domain, the secondary structure of the C-terminal amino acids from positions 485 to 582, as predicted from Chou and Fasman analysis (8) , suggests that it may fold into a helix-loop-helix (9, 44)-like DNA-binding motif. Helix-loop-helix motifs consist of a basic stretch of amino acids that precede two alpha helices that are separated by a loop of variable length. Protein-protein interactions mediated by the alpha helices of two helix-loop-helixcontaining proteins result in the formation of dimers. It is believed that dimerization results in the juxtapositioning of the basic domains of two monomers to yield a dimeric molecule capable of binding DNA. Since there is dyad symmetry in dimeric DNA-binding proteins, it is common for them to bind to palindromic sequences, such as those found in the hr5 enhancer (15 We had previously shown that IEO transactivates p39CATQ-(with enhancer) but does not transactivate p39CAT (without enhancer) (29) . We speculated that if IE1 and IEO transactivate p39CATQ-via the same pathway, A557-582 should interfere with both transactivators. Contrary to our expectation, A557-582 augmented transactivation of the reporter plasmid. We do not believe that A557-582 augments IEO-mediated transactivation by enhancing IEO levels, since it had no effect on IEOCAT expression from the pGCAT reporter (Fig. 4, compare lanes 2 and 9) . Although a number of regulatory mechanisms are possible, we hypothesize (i) that augmentation may occur via an interaction between A557-582 and IEO, which results in a more active form of IEO, or (ii) that A557-582 interacts with a cellular factor that normally competes with IEO for a binding site on hr5, and hence A557-582 functionally sequesters this factor away from the target gene.
The analyses discussed thus far do not directly demonstrate that the various TEl mutants are correctly localized within the transfected cell. The observed regulatory and DNA-binding properties of IE1 lead us to assume that it is a nuclear protein. IE1 has a predicted molecular mass of 70 kDa. This large size suggests that it may have a nuclear localization signal. Deletion of a signal sequence may result in improperly localized mutant polypeptides. If we assume that trans-dominant interference is mediated by direct competition for a common factor(s), proper localization would most probably be essential. The interference assays (Fig. 7) show that all three nontransactivating C-terminal polypeptides expressed interference activity, suggesting that they are probably targeted to the same subcellular compartment(s) as wild-type IEL. Lastly, although the N-terminal mutant A2-145 did not express interference activity, it did repress IEOCAT expression in vivo (Fig. 4, lane 7) , suggesting that this mutant is also localized properly.
Use of transfection assays to probe IEl function. The transient-expression experiments described here provide a reasonable approach to study IE1 gene function. Although the assay has aided us in studying many of the regulatory properties of IE1, the data are limited by the fact that they were obtained in the absence of viral infection. Various attempts to delete the IE1 gene from the AcMNPV genome have failed, suggesting that it may be an essential gene (unpublished results). As a result, extension of this type of mutational analysis to the context of the viral genome has not been possible. Work in our laboratories is currently focusing on the development of inducible promoters for the construction of conditional-lethal mutant viruses, which may enable us to test the various IE1 mutants in the complex environment of the infected cell.
